NCT07326566 2026-03-19
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
30 trialsNCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05503797 2026-03-10
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
Phase 2 Recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT05538130 2026-03-04
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT07042620 2026-02-10
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
SonoClear AS
Phase NA Recruiting
NCT03340506 2026-02-03
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT05355701 2026-02-03
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT06810544 2026-02-02
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07240662 2026-01-09
VIOLETA
iOMEDICO AG
Recruiting
NCT06482905 2026-01-06
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT04943913 2025-12-11
Study of GC101 TIL in Brain Glioma (Soochow2)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT07077616 2025-12-08
TAMAVAQTM
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06910306 2025-12-05
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06326411 2025-11-10
NST-628
Nested Therapeutics, Inc
Phase 1 Recruiting
NCT06011109 2025-10-02
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
Phase 1/2 Recruiting
NCT05736406 2025-09-11
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Recruiting
NCT05580562 2025-08-26
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07025018 2025-08-01
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Hutchmed
Phase 1 Recruiting
NCT05226494 2025-06-04
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals LLC
Phase 1 Recruiting
NCT06687681 2025-04-09
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Kian Immune Cell Company
Phase 2 Recruiting
NCT05460507 2025-03-30
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Plus Therapeutics
Phase 1 Recruiting
NCT01906385 2025-03-26
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Phase 1/2 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT06703255 2025-01-15
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1/2 Recruiting
NCT06496971 2024-11-14
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting